Nephrocare Health IPO (Dec 2025): ₹871 Crore Dialysis Giant with a ₹4,615 Crore Market Cap and a Price Tag That Might Raise Your Blood Pressure
1. At a Glance
If there were ever a hospital stock that could make even your blood pressure machine go “Wow!”, it’s Nephrocare Health Services Ltd. The company — India’s largest dialysis chain and Asia’s leading player — is coming to the market with an ₹871.05 crore IPO. Out of this, ₹353.4 crore is fresh issue, while ₹517.64 crore is an offer for sale (because, obviously, old investors want a partial detox too).
With a price band of ₹438–₹460 per share, the company plans to list on BSE and NSE. The retail investor entry ticket is ₹14,720 for a single lot of 32 shares — that’s like paying for one dialysis session in some private hospitals. The market cap clocks in at ₹4,615 crore (pre-IPO), which is decent, considering Nephrocare’s role in serving around 10% of India’s dialysis patients.
The company’s FY25 financials show a 34% jump in revenue and a 91% surge in profit after tax. But wait — the P/E ratio post-IPO balloons to a stomach-turning 162x, making it look more like a patient on financial steroids than a healthy valuation. Still, in a sector where healthcare demand keeps swelling faster than hospital bills, investors are watching this one like a cardiologist watching an ECG spike.
2. Introduction
In a world where lifestyle diseases have replaced love letters as the most common heartache, Nephrocare Health Services Ltd. decided to build an empire out of our kidney problems. Incorporated in 2010, this Hyderabad-headquartered company operates under the “NephroPlus” brand — and now runs 519 clinics across India and abroad, with more than 5,500 dialysis machines whirring day and night.
Think of Nephrocare as the “Uber of kidneys.” You show up, they hook you to a machine, and out you go a few hours later — lighter, fresher, and financially poorer. Their clinics span from tier-II towns to Uzbekistan (yes, they literally run the world’s largest dialysis center in Uzbekistan).
The IPO opens on December 10, 2025, and closes on December 12, 2025 — with allotment expected by December 15, listing on December 17. It’s led by ICICI Securities, with Kfin Technologies handling the backend. Retail investors can apply for 1–13 lots, while high-net-worth individuals can go up to 68 lots (in case your portfolio needs its own dialysis).
So, what’s the big picture? Nephrocare is betting that India’s chronic disease burden, especially kidney issues, will keep growing. And let’s face it — with our diet of samosas, sugar, and stress, it probably will.
3. Business Model – WTF Do They Even Do?
At its core, Nephrocare Health is a dialysis-as-a-service company. It provides end-to-end kidney care — diagnosis, haemodialysis, home dialysis, mobile dialysis, pharmacy support, and patient wellness programs.
Imagine a chain of clinics where your kidneys are treated better than your boss treats you. They’ve tied up with top hospitals like Fortis, Max, Care Hospitals, Wockhardt, Ruby Hall, and Paras, where Nephrocare runs the dialysis units inside their premises. It’s an asset-light model, meaning hospitals give them space, and Nephrocare brings in the machines, manpower, and management — a win-win for both, unless you’re the patient footing the bill.
Here’s the beauty: 77% of their clinics are in tier II and III cities, where access to quality dialysis care was earlier as rare as a gym membership that gets used. This not only builds goodwill but also gives them a first-mover advantage in rural healthcare expansion.
And it’s not just India — the company has crossed borders into the Philippines, Nepal, and Uzbekistan, because kidney problems clearly don’t need passports. With more than 2.8 million dialysis sessions in FY25, the company handled around 10% of India’s dialysis load — that’s scale, baby!
4. Financials Overview
Let’s get clinical — financially speaking.
Source table
Metric (₹ Cr)
Latest Period (Sep 2025)
YoY (Sep 2024)
Prev (Mar 2025)
YoY %
QoQ %
Revenue
483.97
360.80*
769.92
+34%
-37% (H1 vs FY)
EBITDA
110.31
78.44
166.64
+40%
-33%
PAT
14.23
7.45
67.10
+91%
-78%
EPS (₹)
1.42
0.74
7.24
+92%
-80%
(*approximated from FY24 growth rate)
Commentary: The company’s FY25 numbers are strong — revenue jumped to ₹769.9 crore (from ₹574.7 crore), and PAT nearly doubled to ₹67.1 crore. However, the half-year FY26 PAT is just
